Dr Reddy's
Dr. Reddy’s labs (DRL) has been working hard on its vision to move beyond Generic.Balaglitazone is result of this vision.Positive test results indicate a move in the right direction.If things fall in place DRL is looking at a revenue stream of 2 – 3 billion in the 1st 5 years of launch.Currently the Anti Diabetic market is stagnated with old molecules. Patients have to some extent become immune or respond less to the current drugs on offer a new drug us always welcomed.
Interesting…